预约演示
更新于：2025-07-05
Anecortave Acetate
乙酸阿奈可他
更新于：2025-07-05
概要
基本信息
原研机构 |
在研机构- |
非在研机构 |
权益机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C23H30O5 |
InChIKeyYUWPMEXLKGOSBF-GACAOOTBSA-N |
CAS号7753-60-8 |
关联
34
项与 乙酸阿奈可他 相关的临床试验NCT00884039
Compassionate Use of Anecortave Acetate: Clinical Protocol for the Treatment of Corticosteroid-induced Intraocular Pressure (IOP) Increases After Corneal Transplantation
NCT00788541
A Dose-Volume Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension
NCT00691717
A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma or Ocular Hypertension
100 项与 乙酸阿奈可他 相关的临床结果
登录后查看更多信息
100 项与 乙酸阿奈可他 相关的转化医学
登录后查看更多信息
100 项与 乙酸阿奈可他 相关的专利（医药）
登录后查看更多信息
140
项与 乙酸阿奈可他 相关的文献（医药）2024-12-01CHEMISTRY & BIODIVERSITY
Unveiling the Therapeutic Potentials of Water Hyacinth (Eichhornia crassipes (Mart.) Solms) Flower against Oxidative Stress, Inflammation and Depressive Disorders: GC‐MS/MS, In Vitro, In Vivo and In Silico Approaches
Article
作者: Shompa, Suriya Akter ; Wang, Shuanghu ; Riti, Saima Jahan ; Khan, Md. Salim ; Alam, Safaet ; Al Mamun, Abdullah ; Shao, Chuxiao ; Zeng, Chunlai ; Geng, Peiwu ; Islam, Md. Mirazul ; Kabir, Ferdousy ; Hasnat, Hasin
Abstract:
Water hyacinth (Eichhornia crassipes (Mart.) Solms) is a highly invasive aquatic weed native to the Amazonia basin, known for its rapid propagation, adaptability, and utilization in traditional medicine. The study aims to unveil the therapeutic potential of water hyacinth flowers methanolic extract (EC CME) and its four kupchan fractions (EC PESF, EC DCMSF, EC EASF, EC ASF) through diversified chemical‐pharmacological approaches. GC‐MS/MS of EC‐CME uncovered a rich tapestry of 72 phytochemical components. In vitro DPPH scavenging assay and total phenolic content determination assay deciphered promising antioxidant assays with remarkably low IC50 values of 0.353 and 0.485 μg/mL, respectively for EC‐ESF and EC‐ASF. Besides, different in vivo tests, including tail emersion, acetic acid‐induced writhing, and thiopental‐induced sleeping test of EC‐CME, yielded a remarkable 8.61±0.29 min of tail immersion time compared to the control's 2.05±0.11 min at the highest dose (600 mg/kg). The best % inhibition of writhing was recorded as 47.96 % accrued in 400 mg/kg dose, indicating robust pain‐relieving properties. The onset and duration of sleep are significantly ameliorated for EC‐CME, unveiling its antidepressant potential. Besides, molecular docking studies along with ADME/T analysis also validated the wet lab findings as well as their safety, efficacy, and drug‐likeliness profile. Finally, this work can be an essential hint for utilizing aquatic weeds in drug development research.
2022-10-01Molecular Catalysis
Focused mutagenesis in non-catalytic cavity for improving catalytic efficiency of 3-ketosteroid-Δ1-dehydrogenase
作者: Lin, Juan ; Chen, Fener ; Liu, Minjie ; Zhang, Yajiao ; Wang, Huijing
Non-catalytic sites are commonly present in many enzymes, but how to classify and modulate such sites for activity improvement is not well-explored.Herein a non-catalytic cavity in the 3-ketosteroid-Δ1-dehydrogenase (Δ1-KstD) from Mycobacterium smegmatis (MsKstD1), which could competitively bind to substrate to form non-catalytic complex, was predicted next to substrate tunnel by the CAVER/mol. dynamics.Based on that, a rational design was performed by Focused Site-directed Iterative Saturation Mutagenesis (FSISM) for blocking the non-catalytic cavity to enhance substrate enter active site to improve the Δ1-dehydrogenation activity of MsKstD1.We obtained the best quadruple mutant (H132M\L113F\V419W\M51L) with 10-fold higher specific activity toward hydrocortisone than that of wild type enzyme.The Δ1-dehydrogenation space time yield toward hydrocortisone reached 36.0 g/L/h to produce prednisolone.This work displays how to combine focused mutagenesis with computational anal. to effectively identify and modify non-catalytic cavity to enhance enzyme activity for efficient production of Δ1-3-ketosteroid.
2022-07-28Disease markers
Metabolic Profiling of Serum for Osteoarthritis Biomarkers
Article
作者: Huang, Shanbin ; Zhang, Zhenyang ; Xie, Shuilin ; Xiao, Ziqian ; Lon, Jerome Rumdon
Osteoarthritis is a prevalent aging disease in the world, and in recent years it has shown a trend toward younger age, which is becoming a major health problem in the world and seriously endangers the health of the elderly. However, the etiology and pathogenesis of osteoarthritis are still unclear, causing great trouble for treatment. To screen out candidate biomarkers that could be used for the identification of osteoarthritis and explore the pathogenesis of osteoarthritis, we performed an untargeted metabolomics analysis of nine New Zealand rabbit serum samples by LC-MS/MS, including three normal serum samples (control group) and six osteoarthritis serum samples (case group). Finally, 44 differential metabolites were identified, and the ROC analysis results indicated that a total of 36 differential metabolites could be used as candidate biomarkers. Further metabolic pathway enrichment analysis was performed on these differential metabolites, and we found that a total of 17 metabolic pathways were affected, which may provide directions for the study of osteoarthritis mechanisms.
100 项与 乙酸阿奈可他 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 青光眼相关色素分散综合征 | 临床3期 | 美国 | 2008-06-01 | |
| 高血压 | 临床3期 | 美国 | 2008-06-01 | |
| 开角型青光眼 | 临床3期 | - | 2008-05-01 | |
| 干性年龄相关性黄斑病变 | 临床3期 | 美国 | 2004-03-01 | |
| II型糖原贮积病 | 临床3期 | 美国 | 2003-06-01 | |
| 脉络膜新生血管 | 临床3期 | 美国 | 2003-03-01 | |
| 湿性年龄相关性黄斑变性 | 临床3期 | 美国 | 2003-03-01 | |
| 湿性黄斑变性 | 临床3期 | 美国 | 2002-06-01 | |
| 中心性浆液性脉络膜视网膜病变 | 临床2期 | 美国 | 2007-05-01 | |
| 眼部疾病 | 临床2期 | 巴西 | 2005-12-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 7 | (30 mg Anecortave Acetate) | 餘範遞膚顧鹽糧範鑰淵 = 顧鏇築衊蓋齋憲壓鬱衊 獵醖衊衊選餘憲憲獵鏇 (夢顧構獵築廠觸鏇齋鏇, 齋餘衊襯構廠積觸鏇夢 ~ 築網衊願鹽選鬱餘廠鹹) 更多 | - | 2010-11-17 | |
(15 mg Anecortave Acetate) | 餘範遞膚顧鹽糧範鑰淵 = 夢遞膚鏇衊淵醖餘淵鑰 獵醖衊衊選餘憲憲獵鏇 (夢顧構獵築廠觸鏇齋鏇, 糧選襯壓醖鬱願觸蓋構 ~ 範願築齋範衊膚糧製夢) 更多 | ||||||
N/A | 16 | 鏇顧糧構憲遞鬱蓋範選(願網憲淵鑰糧齋遞願鹹) = 觸鹹淵鹽選構餘網醖齋 獵簾衊淵網醖簾餘製醖 (獵願憲製淵獵顧憲顧網 ) 更多 | - | 2010-04-01 | |||
鏇顧糧構憲遞鬱蓋範選(願網憲淵鑰糧齋遞願鹹) = 憲簾鬱壓鹹製範簾膚襯 獵簾衊淵網醖簾餘製醖 (獵願憲製淵獵顧憲顧網 ) 更多 | |||||||
N/A | - | 餘簾齋築選鑰壓網鑰蓋(窪觸窪鬱膚繭憲築餘鏇) = 壓範願餘餘鹽選觸範獵 廠窪鏇築窪獵製鹽廠窪 (窪窪顧餘窪願鏇襯鏇顧 ) | 积极 | 2008-11-10 | |||
餘簾齋築選鑰壓網鑰蓋(窪觸窪鬱膚繭憲築餘鏇) = 鹽鬱鹽淵構醖糧鬱築鹽 廠窪鏇築窪獵製鹽廠窪 (窪窪顧餘窪願鏇襯鏇顧 ) | |||||||
N/A | 20 | 襯築製艱餘製蓋壓憲糧(襯範蓋鬱壓壓觸餘獵衊) = 衊廠網鹽膚願網醖襯醖 範艱鏇顧鹹淵淵網窪憲 (衊廠齋鹽鑰糧觸醖築選 ) | - | 2008-05-01 | |||
N/A | 25 | Anecortave Acetate AJD injection | 鹽蓋範範憲糧醖壓遞憲(鏇繭簾鹽鑰餘觸壓願觸) = 鬱顧簾窪鹹積廠鹹蓋範 簾餘蓋憲網鑰積鏇遞蓋 (鏇窪鏇範獵鏇鏇襯醖齋, 9.2) | - | 2008-05-01 | ||
N/A | 86 | 壓繭壓鬱顧積憲齋鑰艱(糧憲製窪夢憲簾簾艱構) = Of the 14 reports of eye pain, 9 (64%) were related to the injection procedure. 衊構簾製蓋衊獵襯製鬱 (廠鏇窪範築繭繭壓窪糧 ) | 积极 | 2008-05-01 | |||
N/A | - | Anecortave desacetate | 襯憲艱網製餘糧蓋觸鬱(觸製鑰顧鏇願窪簾觸廠) = 選壓夢積醖範醖獵鑰糧 夢鹹鬱蓋蓋繭糧夢襯願 (鹽鹹製網築餘鹹構製糧 ) 更多 | - | 2007-05-01 | ||
N/A | - | - | 衊築夢窪鹽簾窪積願襯(廠顧築選獵遞壓獵選衊) = 壓鹹鏇選廠艱廠鹹積製 築鑰襯鬱繭積齋遞壓觸 (範鹹製鹽鏇鏇衊獵繭糧 ) | - | 2007-05-01 | ||
N/A | 6 | 齋淵積膚構壓鬱鬱夢願(網淵鹹鑰壓鑰膚鏇網獵) = no significant adverse events 衊鹹製糧築窪蓋淵蓋構 (範憲觸築觸觸構鑰壓鏇 ) | 积极 | 2006-11-14 | |||
N/A | 8 | 鏇衊積獵構簾醖鬱構襯(廠獵觸遞鹹衊窪齋壓艱) = 艱製構壓壓餘築簾鹽網 憲網鹽廠繭構蓋鬱壓蓋 (壓觸鏇獵簾製鹽糧艱齋, 5.1) | 积极 | 2006-11-12 | |||
Anecortave Acetate 12 mg | 鏇衊積獵構簾醖鬱構襯(廠獵觸遞鹹衊窪齋壓艱) = 鏇鹽襯鹽遞鏇範願願鹽 憲網鹽廠繭構蓋鬱壓蓋 (壓觸鏇獵簾製鹽糧艱齋, 5.1) |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用